viral
replicon
selfamplifi
subgenom
viral
rna
form
infecti
particl
safeti
viral
replicon
made
popular
tool
antivir
r
replicon
use
investig
broad
spectrum
antivir
compound
replicon
establish
mani
rna
virus
rna
virus
caus
sever
diseas
dengu
lassa
chikungunya
ebola
mani
virus
propag
high
contain
level
necessit
develop
low
contain
surrog
system
subgenom
replicon
minigenom
system
replicon
selfamplifi
recombin
rna
molecul
express
protein
suffici
replic
produc
infecti
virion
replicon
persist
cell
pass
cell
divis
enabl
quick
effici
highthroughput
test
drug
candid
act
viral
transcript
translat
replic
review
explor
histori
potenti
drug
discoveri
hepat
c
viru
dengu
viru
respiratori
syncyti
viru
ebola
viru
noroviru
replicon
minigenom
system
vaccin
therapeut
main
weapon
deploy
combat
infecti
diseas
vaccin
success
dramat
lower
infect
rate
diseas
like
measl
mump
rubella
diphtheria
pertussi
mani
led
complet
erad
smallpox
nearerad
polio
howev
safe
effect
vaccin
preval
crippl
diseas
known
mankind
remain
elus
despit
decad
research
backdrop
rise
vaccin
hesit
across
world
develop
effect
drug
treatment
patient
suffer
infecti
diseas
imper
howev
drug
lead
discoveri
optimis
infecti
agent
technic
challeng
varieti
reason
cell
cultur
adequ
anim
model
exist
ii
littl
known
biolog
activ
agent
target
iii
agent
requir
categori
contain
facil
avail
academ
industri
research
institut
blueprint
list
prioriti
diseas
exclus
popul
rna
virus
fulfil
one
two
three
criteria
mention
therefor
develop
low
contain
system
highthroughput
hit
discoveri
becom
necess
smallcompound
drug
act
protein
involv
viral
life
cycl
entri
host
cell
viru
uncoat
replic
translat
viral
genom
suppress
innat
host
immun
respons
develop
viral
pseudotyp
viruslik
particl
vlp
made
research
drug
discoveri
viru
entri
uncoat
possibl
reduc
contain
level
contrast
analysi
subgenom
replicon
enabl
uncoupl
viral
replic
transcript
translat
viru
assembl
host
cell
egress
entri
uncoat
replicon
broadli
defin
autonom
replic
dna
rna
molecul
wherea
viral
subgenom
replicon
usual
produc
delet
one
gene
code
structur
protein
insert
replac
report
gene
andor
select
marker
replicon
made
possibl
advent
revers
genet
process
storag
manipul
entir
viral
genom
host
plasmid
recreat
viral
rna
genom
vitro
vivo
transcript
plasmid
case
replicon
establish
plasmiddriven
coexpress
replic
factor
necessari
drive
replic
report
rna
creat
minim
replic
system
term
minigenom
report
rna
usual
contain
genom
untransl
region
utr
essenti
replic
transcript
translat
wherea
replicon
maintain
cell
line
antibiot
select
pass
cell
divis
minigenom
base
plasmid
transfect
limit
lifespan
need
recreat
experiment
although
exhaust
tabl
list
establish
replicon
minigenom
system
mani
medic
relev
virus
sinc
concept
replicon
minigenom
use
lowand
highthroughput
screen
compound
librari
elucid
biolog
mechan
drug
action
screen
drug
escapemut
aris
repliconharbour
cell
pool
owe
gener
poor
fidel
viral
rnadepend
rna
polymeras
rdrp
review
briefli
cover
modern
success
stori
establish
use
subgenom
replicon
develop
drug
hepat
c
viru
hcv
illustr
potenti
dengu
viru
togaviru
respiratori
syncyti
viru
noroviru
replicon
ebola
viru
minigenom
discoveri
smallmolecul
inhibitor
recent
year
replicon
deriv
virus
hepat
e
viru
enteroviru
sever
acut
respiratori
syndrom
viru
among
other
descript
beyond
scope
review
estim
million
peopl
infect
hcv
global
infect
individu
likelihood
develop
chronic
infect
left
untreat
lead
liver
cirrhosi
hepatocarcinoma
previou
first
directact
antivir
daa
releas
market
pegyl
interferon
ifn
combin
ribavirin
use
standard
therapi
aviraemia
week
complet
antivir
therapi
depend
viral
genotyp
hcv
hepaciviru
within
flavivirida
famili
singlestrand
positivesens
rna
genom
knt
kilo
nucleotid
hcv
genom
encod
polyprotein
proteolyt
cleav
viral
cellular
proteas
three
structur
protein
core
envelop
protein
envelop
protein
seven
nonstructur
protein
hcv
strain
establish
product
infect
cell
cultur
shown
first
strain
could
propag
cell
cultur
system
without
adapt
mutat
overcom
limit
lohmann
et
al
defin
minim
set
hcv
protein
necessari
facilit
autonom
replic
replac
code
region
core
envelop
protein
neomycin
resist
cassett
express
driven
encephalomyocard
viru
emcv
intern
ribosom
entri
site
ire
establish
bicistron
hcv
replicon
figur
develop
start
daa
discoveri
eventu
led
licens
firstgener
daa
boceprevir
telaprevir
proteas
inhibitor
replicon
use
assess
efficaci
bioavail
drug
candid
well
analysi
escap
mutant
discoveri
optimis
candid
review
howev
boceprevir
telaprevir
act
hcv
genotyp
make
develop
subgenom
replicon
genotyp
necessari
facilit
discoveri
drug
act
genotyp
date
subgenom
replicon
develop
hcv
strain
ensur
test
pangenotyp
effect
drug
candid
replicon
system
aid
develop
secondgener
daa
ledipasvir
act
viral
regulatori
protein
sofosbuvir
nucleotid
phosphoramid
prodrug
inhibit
polymeras
without
develop
hcv
replicon
daa
develop
would
sever
delay
imposs
first
time
histori
patient
cure
hcv
daa
combin
therapi
dengu
serotyp
virus
arthropodborn
flavivirus
spread
aed
mosquito
estim
million
peopl
infect
dengu
viru
everi
year
despit
high
proport
infect
asymptomat
million
case
dengu
diseas
diagnos
annual
roughli
symptomat
patient
progress
dengu
haemorrhag
fever
andor
dengu
shock
syndrom
requir
hospitalis
fatal
date
approv
specif
drug
treatment
avail
dengu
viru
dengu
viru
singlestrand
positivesens
rna
genom
size
roughli
knt
translat
amino
acid
polyprotein
polyprotein
process
viral
cellular
proteas
three
structur
protein
capsid
premembran
envelop
seven
nonstructur
ns
protein
harbour
ntermin
methyltransferas
ctermin
rdrp
activ
addit
utr
first
nucleotid
capsid
code
region
contain
hairpin
element
cyclis
motif
essenti
replic
replicon
establish
pang
et
al
delet
premembran
envelop
protein
code
region
show
denv
amen
analysi
replicon
around
time
replicon
establish
close
relat
virus
like
kunjin
west
nile
yellow
fever
viru
select
denv
replicon
harbour
report
gene
report
multipl
group
construct
replac
envelop
excis
code
region
ctermin
portion
capsid
end
envelop
replac
varieti
report
gene
includ
fluoresc
protein
luciferas
combin
report
gene
antibiot
resist
cassett
replicon
two
foreign
gene
eg
report
resist
cassett
translat
nonstructur
protein
driven
ire
sequenc
translat
report
driven
viral
utr
report
separ
antibiot
resist
footandmouth
diseas
viru
fmdv
autoproteas
enabl
posttransl
cleavag
report
resist
marker
figur
dengu
replicon
system
success
use
hit
discoveri
lu
et
al
identifi
phthalazinon
deriv
potent
inhibitor
replic
frabasil
et
al
use
similar
screen
show
naringenin
citru
flavonon
greatli
impair
genom
replic
use
human
cell
harbour
replicon
hernandezmoral
et
al
test
hcv
compound
librari
highthroughput
replicon
screen
assay
identifi
effect
lead
public
show
subgenom
replicon
system
use
detect
druginduc
resistanceassoci
mutat
case
resistanceassoci
mutat
found
cluster
code
region
interestingli
known
enzymat
activ
essenti
replic
known
interact
viral
cellular
protein
form
dengu
replic
complex
subvert
cellular
innat
immun
respons
quinic
acid
deriv
shown
reduc
amount
treat
repliconcontain
cell
fac
analysi
interestingli
genom
replic
translat
exclud
mode
action
drug
candid
hirsutin
use
dengu
subgenom
replicon
system
dengu
viru
drug
discoveri
hotb
activ
recent
review
howev
none
aforement
drug
candid
taken
clinic
chikungunya
viru
chikv
western
eastern
venezuelan
equin
enceph
viru
weev
eeev
veev
sindbi
viru
sinv
promin
member
togavirida
famili
chikv
transmit
aed
mosquito
caus
symptom
fever
rash
joint
muscl
pain
veev
confin
central
south
america
infect
human
caus
flulik
symptom
healthi
individu
sever
ill
death
immunosuppress
viru
weaponis
usa
soviet
union
sinv
wide
geograph
distribut
caus
fever
rash
polyarthr
myalgia
human
member
togavirida
famili
singlestrand
positivesens
rna
virus
genom
knt
size
featur
cap
polya
tail
togaviru
genom
code
two
polyprotein
nonstructur
structur
polyprotein
nonstructur
polyprotein
produc
direct
translat
genom
structur
polyprotein
produc
translat
subgenom
rna
produc
viral
rdrp
promot
locat
two
code
region
structur
polyprotein
process
four
structur
protein
capsid
nonstructur
polyprotein
proteolyt
process
four
nonstructur
protein
interact
form
replic
complex
review
first
togaviru
replicon
establish
sinv
replac
region
code
structur
polyprotein
chloramphenicol
transferas
cat
gene
howev
replicon
sinv
chikv
old
world
togavirus
use
wildtyp
viral
sequenc
caus
cytopath
effect
host
cell
could
propag
cell
cultur
prolong
period
time
found
caus
nuclear
transloc
result
cytotox
case
chikv
semliki
forest
viru
replicon
mutat
nuclear
localis
sequenc
essenti
achiev
noncytopath
replicon
phenotyp
interestingli
replicon
wildtyp
sequenc
veev
newworld
togaviru
show
cytopath
effect
dengu
replicon
sever
report
gene
andor
antibiot
select
marker
use
replac
cat
fluoresc
protein
luciferas
either
alon
conjunct
antibiot
resist
gene
separ
fmdv
autoproteas
figur
replicon
use
screen
drug
candid
act
transcript
replic
machineri
togavirida
famili
member
lead
compound
identifi
past
year
includ
abamectin
ivermectin
berberin
plantderiv
isoquinolin
alkaloid
abamectin
ivermectin
wide
use
antihelminth
followup
studi
conduct
antivir
effect
chikv
howev
phase
iiiii
trial
ongo
assess
safeti
efficaci
ivermectin
use
denv
infect
followup
studi
berberin
shown
inhibit
map
kinas
pathway
activ
chikv
infect
show
effect
allevi
symptom
chikv
infect
mous
model
howev
clinic
studi
follow
weev
replicon
use
highthroughput
studi
use
librari
extract
marin
organ
divers
geograph
region
thirtyseven
primari
hit
identifi
primari
hit
antimycin
deriv
marin
actinomycet
streptomyc
kaviengensi
isol
promis
antimycin
promin
broadspectrum
antivir
inhibit
cellular
mitochondri
electron
transport
chain
de
novo
pyrimidin
synthesi
besid
drug
discoveri
togaviru
replicon
modifi
success
use
platform
express
heterolog
recombin
protein
vaccin
platform
rsv
common
caus
acut
lower
respiratori
infect
estim
million
case
report
death
hospitalis
children
year
age
modern
vaccin
effort
well
way
sever
major
pharma
compani
disastr
failur
firstgener
formalininactiv
whole
viru
vaccin
date
ribavirin
smallmolecul
broadband
antivir
palivizumab
monoclon
antibodi
target
viral
fusion
protein
approv
treatment
prevent
rsv
rsv
member
paramyxovirida
famili
envelop
viru
nonseg
singlestrand
negativesens
rna
genom
knt
genom
code
protein
small
hydrophob
protein
sh
attach
protein
g
fusion
protein
f
matrix
protein
nucleoprotein
n
phosphoprotein
p
larg
protein
l
harbour
rdrp
activ
transcript
regul
transcriptionrepl
regulatori
protein
two
nonstructur
protein
rsv
handl
biosafeti
level
howev
major
viru
progeni
cell
cultur
filament
extrem
fragil
therefor
minigenom
system
develop
base
plasmiddriven
express
l
n
p
protein
form
ribonucleoprotein
complex
within
transfect
cell
togeth
rna
molecul
consist
leader
trailer
sequenc
rsv
genom
region
code
cat
figur
system
mainli
use
elucid
replic
transcript
rsv
genom
although
drug
lead
found
includ
inhibitor
cotranscript
rna
guanylyl
true
rsv
replicon
establish
replac
sh
g
f
code
region
select
marker
blasticidin
deaminas
bla
replicon
found
stabl
noncytopath
sever
cell
line
could
packag
vlp
coexpress
structur
protein
sh
g
f
tran
transfer
differ
cell
line
infect
result
transpackag
vlp
figur
replicon
system
use
ht
specif
antirsv
drug
act
replic
machineri
viru
smallmolecul
compound
found
inhibit
transcript
replic
initi
find
later
confirm
use
minigenom
system
lagana
et
al
screen
astra
zeneca
compound
librari
highthroughput
approach
use
rsv
replicon
identifi
three
new
lead
compound
nucleosid
analogu
nonnucleosid
inhibitor
rsv
rdrp
nucleosid
analogu
polymeras
inhibitor
screen
use
replicon
cell
line
compound
found
firstinclass
smallmolecul
inhibitor
rsv
replic
act
chain
termin
replic
compound
abandon
johnson
johnson
march
phase
iib
trial
noroviru
origin
identifi
outbreak
winter
vomit
diseas
norwalk
ohio
diseas
manifest
selflimit
fulmin
vomit
diarrhoea
lowgrad
fever
last
h
estim
per
year
noroviru
prompt
hospit
visit
develop
world
estim
death
children
year
age
develop
world
despit
high
viru
titer
stool
infect
success
cultur
murin
norovirus
primari
murin
cell
human
norovirus
elud
effici
propag
cell
cultur
far
human
norovirus
found
produc
low
viru
titer
b
cell
model
differenti
cell
howev
data
controversi
circumv
lack
viru
propag
cell
cultur
noroviru
replicon
establish
human
norovirus
nonenvelop
positivesens
singlestrand
rna
virus
belong
famili
calicivirida
genom
size
vari
knt
contain
three
open
read
frame
code
polyprotein
posttransl
process
proteas
six
nonstructur
protein
proteas
rdrp
cap
viral
rna
rna
helicas
implic
format
replic
complex
translat
subgenom
rna
major
minor
capsid
protein
respect
review
short
utr
flank
orf
contain
secondari
structur
stretch
code
region
essenti
replic
transcript
pathogenesi
plasmidbas
infecti
clone
nv
base
norwalk
strain
establish
contain
cdna
full
viru
genom
control
promot
base
nv
chang
et
al
establish
replicon
replac
major
code
region
neomycin
phosphotransferas
npt
gene
figur
transfect
bhk
cell
express
polymeras
repliconcod
plasmid
result
cell
line
maintain
replicon
select
replicon
could
transfer
cell
rna
extract
transfect
result
rna
maintain
passag
select
grouta
lab
witchita
state
univers
ration
design
proteas
inhibitor
noroviru
virus
test
compound
use
replicon
system
review
four
nucleosid
analogu
test
noroviru
replicon
show
good
antivir
activ
rupintrivir
proteas
inhibitor
rhinoviru
proteas
shown
clear
cell
noroviru
replicon
howev
owe
fact
noroviru
infect
shortliv
selflimit
interest
pharma
compani
develop
smallmolecul
inhibitor
limit
none
mention
candid
taken
forward
clinic
trial
although
true
replicon
ebola
viru
minigenom
integr
part
ebola
viru
basic
research
inhibitor
discoveri
ebov
outbreak
sierra
leon
liberia
guinea
ongo
epidem
democrat
republ
congo
led
sharp
increas
fund
effort
develop
vaccin
therapeut
ebola
relat
filovirus
ebov
caus
viral
haemorrhag
fever
mortal
rate
viru
handl
bsl
condit
ebov
negativesens
singlestrand
rna
viru
ebov
genom
knt
size
code
eight
major
viral
protein
nucleoprotein
np
glycoprotein
gp
solubl
glycoprotein
sgp
larg
protein
l
l
protein
harbour
rdrp
activ
togeth
np
constitut
ribonucleoprotein
complex
former
three
protein
suffici
replic
essenti
transcript
minigenom
system
consist
rna
molecul
carri
nativ
leader
trailer
sequenc
genom
express
cassett
insert
antisens
direct
code
either
cat
luciferas
green
fluoresc
protein
gfp
figur
classic
cell
cotransfect
plasmid
code
l
np
cell
transfect
vitro
transcrib
minigenom
rna
lead
replic
transcript
minigenom
within
transfect
cell
ultim
express
report
gene
year
improv
made
system
cell
line
stabli
express
l
np
minimis
variabl
introduc
cotransfect
plasmid
select
marker
coexpress
report
creation
stabl
cell
line
continu
replic
minigenom
express
minigenom
within
cell
transfect
plasmid
code
minigenom
polymeras
minigenom
system
use
either
smallscal
highthroughput
system
identif
lead
compound
angelicin
deriv
benzoquinolon
two
anticanc
drug
heatshock
protein
hsp
inhibitor
howev
date
none
compound
taken
clinic
phase
use
antivir
advent
revers
genet
establish
stabl
repliconharbour
cell
line
minigenom
further
understand
molecular
biolog
virus
facilit
advanc
antivir
drug
discoveri
absenc
viabl
cell
cultur
system
virus
requir
highcontain
facil
replicon
still
invalu
tool
drug
discoveri
conflict
interest
declar
intern
ribosom
entri
site
ire
footandmouth
diseas
viru
autoproteas
sequenc
mark
line
arrow
respect
minigenom
f
plasmiddriven
express
viral
gene
shown
circular
line
hepat
c
viru
hcv
genom
ai
deriv
replicon
aii
hcv
replicon
establish
replac
c
neomycin
phosphotransferas
neo
translat
driven
ire
sequenc
b
dengu
viru
denv
genom
bi
deriv
replicon
bii
iii
replicon
dengu
viru
produc
replac
ctermin
part
c
full
length
prm
ntermin
part
e
either
green
fluoresc
protein
gfp
cleav
sequenc
bii
polyprotein
cleav
sequenc
produc
puromycinnacetyl
transferas
pac
enhanc
gfp
egfp
translat
driven
ire
sequenc
biii
c
togavirida
genom
ci
deriv
replicon
chikungunya
viru
